Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13001
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNarkwichean A.
dc.contributor.authorMaalouf W.
dc.contributor.authorBaumgarten M.
dc.contributor.authorPolanski L.
dc.contributor.authorRaine-Fenning N.
dc.contributor.authorCampbell B.
dc.contributor.authorJayaprakasan K.
dc.date.accessioned2021-04-05T03:21:59Z-
dc.date.available2021-04-05T03:21:59Z-
dc.date.issued2017
dc.identifier.issn3012115
dc.identifier.other2-s2.0-85029532377
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/13001-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85029532377&doi=10.1016%2fj.ejogrb.2017.09.006&partnerID=40&md5=9356158b78b61815f6d573dc4e140642
dc.description.abstractObjective To evaluate the effect of DHEA supplementation on In-Vitro Fertilisation (IVF) outcome as assessed by ovarian response, oocyte developmental competence and live birth rates in women predicted to have poor ovarian reserve (OR). The feasibility of conducting a large trial is also assessed by evaluating the recruitment rates and compliance of the recruited participants with DHEA/placebo intake and follow-up rates. Study design A single centre, double blinded, placebo controlled, randomized trial was performed over two years with 60 women undergoing in-vitro fertilisation (IVF). Subjects were randomized, based on a computer-generated pseudo-random code to receive either DHEA or placebo with both capsules having similar colour, size and appearance. 60 women with poor OR based on antral follicle count or anti-Mullerian hormone thresholds undergoing IVF were recruited. They were randomised to receive DHEA 75 mg/day or placebo for at-least 12 weeks before starting ovarian stimulation. They had long protocol using hMG 300 IU/day. Data analysed by “intention to treat”. Ovarian response, live birth rates and molecular markers of oocyte quality were compared between the study and control groups. Results The recruitment rate was 39% (60/154). A total of 52 participants (27 versus 25 in the study and placebo groups) were included in the final analysis after excluding eight. While the mean (standard deviation) DHEA levels were similar at recruitment (9.4 (5) versus 7.5 (2.4) ng/ml; P = 0.1), the DHEA levels at pre-stimulation were higher in the study group than in the controls (16.3 (5.8) versus 11.1 (4.5) ng/ml; P < 0.01). The number (median, range) of oocytes retrieved (4, 0–18 versus 4, 0–15 respectively; P = 0.54) and live birth rates (7/27, 26% versus 8/25, 32% respectively; RR (95% CI): 0.74 (0.22-2.48) and mRNA expression of developmental biomarkers in granulosa and cumulus cells were similar between the groups. Conclusion Pre-treatment DHEA supplementation, albeit statistical power in this study is low, did not improve the response to controlled ovarian hyperstimulation or oocyte quality or live birth rates during IVF treatment with long protocol in women predicted to have poor OR. © 2017
dc.subjectampiregulin
dc.subjectbetaregulin
dc.subjectbiological marker
dc.subjectbuserelin
dc.subjectchorionic gonadotropin
dc.subjectcyclooxygenase 2
dc.subjectepiregulin
dc.subjectfollitropin receptor
dc.subjectGREM1 protein
dc.subjecthuman menopausal gonadotropin
dc.subjecthyaluronan synthase 2
dc.subjectluteinizing hormone receptor
dc.subjectmessenger RNA
dc.subjectmolecular marker
dc.subjectMuellerian inhibiting factor
dc.subjectnafarelin
dc.subjectnafarelin acetate
dc.subjectpentraxin 3
dc.subjectplacebo
dc.subjectprasterone
dc.subjectprogesterone
dc.subjectPTGS2 protein
dc.subjectsomatomedin C
dc.subjectunclassified drug
dc.subjectandrogen
dc.subjectprasterone
dc.subjectacne
dc.subjectadult
dc.subjectantral follicle count
dc.subjectArticle
dc.subjectbirth rate
dc.subjectclinical outcome
dc.subjectcontrolled study
dc.subjectcumulus cell
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug withdrawal
dc.subjectembryo
dc.subjectembryo transfer
dc.subjectfemale
dc.subjectfollow up
dc.subjectgastrointestinal symptom
dc.subjectgene expression profiling
dc.subjectgranulosa cell
dc.subjecthuman
dc.subjectin vitro fertilization
dc.subjectintention to treat analysis
dc.subjectintracytoplasmic sperm injection
dc.subjectlive birth
dc.subjectmajor clinical study
dc.subjectnausea
dc.subjectoily skin
dc.subjectoocyte development
dc.subjectoocyte retrieval
dc.subjectovarian reserve
dc.subjectovary hyperstimulation
dc.subjectpregnancy outcome
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectsingle embryo transfer
dc.subjectaging
dc.subjectdrug effect
dc.subjectmetabolism
dc.subjectoocyte
dc.subjectovary
dc.subjectovulation induction
dc.subjectpregnancy
dc.subjectprocedures
dc.subjectAdult
dc.subjectAging
dc.subjectAndrogens
dc.subjectDehydroepiandrosterone
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectFertilization in Vitro
dc.subjectHumans
dc.subjectIntention to Treat Analysis
dc.subjectLive Birth
dc.subjectOocyte Retrieval
dc.subjectOocytes
dc.subjectOvarian Reserve
dc.subjectOvary
dc.subjectOvulation Induction
dc.subjectPregnancy
dc.titleEfficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationEuropean Journal of Obstetrics and Gynecology and Reproductive Biology. Vol 218, (2017), p.39-48
dc.identifier.doi10.1016/j.ejogrb.2017.09.006
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.